Results with Lifescozul™Prostate Cancer
Introduction to the case
Prostate cancer forms in the cells of the prostate gland.
Many prostate cancers grow slowly and are unlikely to spread, but some can grow more rapidly.
Prostate cancer is the second most common cancer in men worldwide and mainly affects older men.
Prostate cancer mainly affects older men: more than half of prostate cancers occur in men over the age of 70.
It is the second most common cancer in men worldwide. The highest incidence of prostate cancer is reported in Australia/New Zealand, North America and Northern and Western Europe.
Today we comment on the evolution of Mr. Juan Jose Rodriguez, who has been on treatment with LifEscozul, the most advanced and effective formulation made from blue scorpion venom, since 2018.
Juan Jose Rodriguez, Male, 56 years old at the beginning of treatment with LifEscozul.
insomnio, depresión, buena condición física en general.
Acinar adenocarcinoma of the prostate, without apparent metastases.
Mr. Juan Jose was diagnosed with prostate cancer discovered after 3 biopsies, which were performed due to successive increases in PSA.
"The diagnosis of prostate cancer is usually based on the results of a clinical examination of the prostate and a blood test in which the levels of a protein called prostate specific antigen (PSA) are checked, as well as the results of a biopsy."
At this point the local doctor offered Juan the choice of surgery, radiation therapy or active follow-up.
Juan decided to choose active follow-up.
However he decided to enter the Protocol and started in November 2018 treatment with LifEscozul (escozul, blue scorpion venom) under a regimen of concentrated and gradually increased doses.
Evolution with LifEscozul™ and actual results
It has been Juan Jose's wife who has been in communication with our team of doctors and specialists throughout Juan Jose's treatment with LifEscozul.
Before starting the LifEscozul treatment
When doing Juan's case description, prior to starting treatment, indicators were analyzed highlighting the PSA value in October 2018 which was 8.10.
Part of our goals is always to measure indicators. PSA is a direct indicator of tumor activity, and is considered a reference to measure tumor aggressiveness.
Three months into the LifEscozul Protocol.
In February 2019, 3 months into the LifEscozul (escozul, blue scorpion venom) Protocol, the patient's condition is assessed and the PSA value is compared.
At this point of the treatment, Juan no longer refers episodes of anxiety or depression. His wife commented that Juan Jose had no discomfort or discomfort.
More importantly, his PSA value had decreased slightly from 8.10 to 7.93.
6 months after the LifEscozul Protocol was initiated.
In May 2019, it was decided to perform a prostate biopsy on Juan Jose, which was negative for the presence of cancer.
At this point Juan's quality of life was very good and this news contributed more to strengthen his mental state.
9 months into the LifEscozul Protocol
By September 2019 a test was requested to measure the PSA value which continued to decrease to 7.56.
And by April 2020 the value was at 6.95.
As of today, Juan Jose's quality of life remains in good condition, waiting for the Covid pandemic to pass so that he can undergo new tests.
In prostate cancer, early detection is vital.
This was the case of Juan Jose, who was found to have prostate cancer even without metastasis.
Among the most outstanding results of the LifEscozul Protocol was the control of PSA, the prostate antigen, the indicator par excellence of tumor activity. This indicator kept decreasing for two years without increasing even once.
However, the most important result was obtained through a biopsy, the result of which indicated the absence of the tumor.
Undoubtedly an impressive result, especially because Juan gradually improved his quality of life and has managed to maintain it.
Undoubtedly, the dedication, effort and knowledge of our experts made the difference in finding the right dose for such a response.
We are the LifEscozul Group and the Results Define Us.
In 2016 Hector was diagnosed with a grade I bladder carcinoma. To treat his disease they proposed chemotherapy and BCG immunotherapy, but Hector refused both treatments. View more